{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:57:17Z","timestamp":1785419837971,"version":"3.56.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:p>Mining and updating the post-marketing safety signals of esketamine nasal spray for better identification of adverse drug event (ADE) signals and medication monitoring during clinical use to ensure patient medication safety. Downloading data from the US Food and Drug Administration Adverse Event Reporting System from Q1 2019 to Q2 2023, the reporting odds ratio, proportional reporting ratio, Multi-item Gamma Poisson Shrinker, and Bayesian Confidence Propagation Neural Network methods of the disproportionality method were used to mine and analyze ADEs, and finally to screen for signals of ADEs with esketamine nasal spray as the primary suspected drug. The Preferred Terminology of the Medical Dictionary of Regulatory Activities (version 26.0) was used to standardize the description of ADEs and to attribute ADEs to the System Organ Classification. A total of 5132 ADEs reports of esketamine nasal spray as the primary suspected drug were obtained from the Food and Drug Administration Adverse Event Reporting System. The most frequently observed ADEs are dissociation, sedation, and hypertension, while some new rare signals have been detected, such as interstitial cystitis, substance abuse, and drug diversion. The present study identified significant new ADEs signals for esketamine nasal spray, which may provide a source for healthcare professionals to assess patients\u2019 symptoms and risk identification.<\/jats:p>","DOI":"10.1097\/md.0000000000039484","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:12:22Z","timestamp":1730884342000},"page":"e39484","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["A real-world pharmacovigilance study of esketamine nasal spray"],"prefix":"10.1097","volume":"103","author":[{"given":"Yaqing","family":"Chen","sequence":"first","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangye","family":"Gu","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Li","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4387-403X","authenticated-orcid":false,"given":"Yong","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250505","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.","volume":"172","author":"Newport","year":"2015","journal-title":"Am J Psychiatry"},{"key":"R2-20250505","doi-asserted-by":"crossref","first-page":"113935","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"R3-20250505","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial.","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"R4-20250505","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1060028019892644","article-title":"Esketamine: a novel option for treatment-resistant depression.","volume":"54","author":"Bozymski","year":"2020","journal-title":"Ann Pharmacother"},{"key":"R5-20250505","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study.","volume":"80","author":"Singh","year":"2016","journal-title":"Biol Psychiatry"},{"key":"R6-20250505","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.encep.2021.12.002","article-title":"L\u2019efficacit\u00e9 de l\u2019esk\u00e9tamine dans le trouble d\u00e9pressif majeur r\u00e9sistant : une revue syst\u00e9matique de la litt\u00e9rature [The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature].","volume":"48","author":"Mungo","year":"2022","journal-title":"Encephale"},{"key":"R7-20250505","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation.","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"R8-20250505","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression.","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"R9-20250505","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study.","volume":"264","author":"Correia-Melo","year":"2020","journal-title":"J Affect Disord"},{"key":"R10-20250505","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study.","volume":"175","author":"Canuso","year":"2018","journal-title":"Am J Psychiatry"},{"key":"R11-20250505","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval.","volume":"6","author":"Turner","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"R12-20250505","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-Marketing Safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system.","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother Psychosom"},{"key":"R13-20250505","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting: quantitative signal detection.","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R14-20250505","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/2168479013514236","article-title":"A review of statistical methods for safety surveillance.","volume":"48","author":"Huang","year":"2014","journal-title":"Ther Innov Regul Sci"},{"key":"R15-20250505","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.yfrne.2014.05.004","article-title":"Sex differences in anxiety and depression clinical perspectives.","volume":"35","author":"Altemus","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"R16-20250505","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1017\/S2045796019000751","article-title":"Esketamine for treatment resistant depression: a trick of smoke and mirrors?","volume":"29","author":"Gastaldon","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"key":"R17-20250505","doi-asserted-by":"crossref","first-page":"428176","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study.","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"R18-20250505","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1464-410X.2012.11028.x","article-title":"The prevalence and natural history of urinary symptoms among recreational ketamine users.","volume":"110","author":"Winstock","year":"2012","journal-title":"BJU Int"},{"key":"R19-20250505","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1757-5672.2011.00101.x","article-title":"Ketamine-induced uropathy: a new clinical entity causing lower urinary tract symptoms.","volume":"4","author":"Chang","year":"2012","journal-title":"Low Urin Tract Symptoms"},{"key":"R20-20250505","first-page":"1","article-title":"Aldh2 gene reduces oxidative stress in the bladder by regulating the NF\u2011&kappa;B pathway in a mouse model of ketamine\u2011induced cystitis.","volume":"20","author":"Xi","year":"2020","journal-title":"Exp Ther Med"},{"key":"R21-20250505","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1038\/s41467-020-18167-4","article-title":"Disruption of Cav1.2-mediated signaling is a pathway for ketamine-induced pathology.","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"R22-20250505","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/nau.22367","article-title":"Dual involvements of cyclooxygenase and nitric oxide synthase expressions in ketamine\u2010induced ulcerative cystitis in rat bladder.","volume":"32","author":"Chuang","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"R23-20250505","doi-asserted-by":"crossref","first-page":"e21703","DOI":"10.1096\/fj.202100437","article-title":"Molecular pathways underlying tissue injuries in the bladder with ketamine cystitis.","volume":"35","author":"Xie","year":"2021","journal-title":"FASEB J"},{"key":"R24-20250505","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/fcp.12745","article-title":"Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti\u2010depressive drug on the market.","volume":"36","author":"Baudot","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"R25-20250505","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/ijerph15092028","article-title":"Suicide risk and mental disorders.","volume":"15","author":"Br\u00e5dvik","year":"2018","journal-title":"Int J Environ Res Public Health"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T20:02:26Z","timestamp":1746475346000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":25,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039484","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}